A Phase 3 interventional study of TVB-009 and Prolia® in Osteoporosis, Postmenopausal, sponsored by Teva Pharmaceuticals USA. Completed at 78 sites in 10 countries. Open to female participants aged 60 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing denosumab in Osteoporosis, Postmenopausal — 1 open to participants now, 3 under way, 2 of them phase 3. Denosumab · Osteoporosis, Postmenopausal.
Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, this one is the 14th largest by enrollment, is one of 3 that started in 2021, is one of 17 in phase 3, and was the 25th registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →1 of the 31 studies testing denosumab in Osteoporosis, Postmenopausal is open now, in 1 country. Recruiting first, the newest first:
Lambda Therapeutic Research Ltd. · Sites in India
Ages 55–90 · Women only
By country, each count listing its studies:
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 60 Years to 90 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 332 is above the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 278 across the 31 interventional studies. Of the 27 that completed or were terminated, 20 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 31 have an industry lead sponsor. The 10 most frequent:
This study is registered under Teva Pharmaceuticals USA, one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Teva Pharmaceutical Industries, Ltd. has 1 study filed under Osteoporosis, Postmenopausal — fewer than ten, so there is no comparison to draw.
1 of the studies testing denosumab in Osteoporosis, Postmenopausal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05010590Massachusetts General HospitalAnabolic Therapy in Postmenopausal Osteoporosis | 2027-10-01 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate similar efficacy and safety between TVB-009 and Prolia® (denosumab)
This is a multinational, multicenter, randomized, double-blind study to demonstrate similar efficacy and safety of TVB-009 compared to Prolia® administered subcutaneously at doses of 60 mg every 26 weeks. Approximately 326 postmenopausal women with osteoporosis will be randomized to receive either TVB-009 or Prolia®. At week 52, patients in the Prolia® arm will be re-randomized 1:1 to either continue with a third dose of Prolia® or transition to TVB-009 and receive a single dose of TVB-009 in the transition period to assess immunogenicity and safety after a transition from Prolia® to TVB-009. The total treatment duration for each patient is 78 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other Inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TVB-009 (denosumab) pre-filled syringe, administered at weeks 1 and 26
Combination Product: TVB-009
Prolia® (denosumab) pre-filled syringe, administered at weeks 1 and 26
Combination Product: Prolia®
TVB-009 (denosumab) pre-filled syringe, administered at week 52 in patients that were randomized to TVB-009 in the main treatment period
Combination Product: TVB-009
Prolia® (denosumab) pre-filled syringe, administered at week 52 in patients that were randomized to PROLIA in the main treatment period
Combination Product: Prolia®
TVB-009 (denosumab) pre-filled syringe, administered at week 52 in patients that were randomized to PROLIA in the main treatment period
Combination Product: TVB-009 · Combination Product: Prolia®
TVB-009 Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)
Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)
Percent Change From Baseline in LS-BMD at Week 52
Percent change from baseline in lumbar spine bone mineral density (LS BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 52
Time frame: Baseline and week 52
Percent Change From Baseline in sCTX-1 at Week 26
Percent change from baseline in serum C-telopeptide cross-link of type 1 collagen at week 26
Time frame: Baseline and week 26
Percent Change From Baseline in LS-BMD at Week 26
Percent change from baseline in lumbar spine bone mineral density (LS BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 26
Time frame: Baseline and week 26
Percent Change From Baseline in Femoral Neck BMD at Week 26
Percent change from baseline in femoral neck bone mineral density (BMD) based on centrally assessed dual energy X ray absorptiometry (DXA)at week 26
Time frame: Baseline, week 26
Percent Change From Baseline in Total Hip BMD at Week 26
Percent change from baseline in total hip bone mineral density (BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 26
Time frame: Baseline, week 26
Percent Change From Baseline in sCTX-1
Percent change from baseline in serum C-telopeptide cross-link of type 1 collagen
Time frame: Baseline through Week 52
Percentage of Participatns With sCTX-1 Suppression at Week 4
Proportion of patients with suppression of serum C-telopeptide cross-link of type 1 collagen at week 4
Time frame: Week 4
Percent Change From Baseline in P1NP
Percent change from baseline in procollagen type 1 N propeptide (P1NP) to Week 52
Time frame: Baseline through Week 52
Number of Fractures up to Week 52
Number of patients with who experienced any new fractures up to week 52.
Time frame: Up to week 52
Percent Change From Week 52 in LS-BMD by DXA at Week 78
Percent change from week 52 in lumbar spine bone mineral density (LS BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 78
Time frame: Week 52 through week 78
Percent Change From Week 52 in Femoral Neck BMD by DXA at Week 78
Percent change from week 52 in femoral neck bone mineral density (LS BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 78
Time frame: Week 52 through week 78
Percent Change From Week 52 in Total Hip BMD by DXA at Week 78
Percent change from week 52 in total hip bone mineral density (LS BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 78
Time frame: Week 52 through week 78
Difference Between Percent Change From Baseline in sCTX-1 Between Week 52 and Week 78
Difference in the percent change from baseline in serum C-telopeptide cross-link of type 1 collagen from baseline to Week 78 as compared to baseline to Week 52
Time frame: Baseline, Week 52, Week 78
Difference Between Percent Change From Baseline in P1NP Between Week 52 and Week 78
The difference in the Percent change from baseline in procollagen type 1 N propeptide at Week 78 compared to Week 52.
Time frame: Baseline, Week 52, Week 78
Number of Patients With Fractures Between Week 52 and Week 78
Number of patients experiencing new fractures between week 52 and week 78
Time frame: Week 52 through week 78
Incidence of Adverse Event
Number of patients reporting at least one treatment-emergent adverse event up to week 52
Time frame: Up to week 52
Incidence of Adverse Events in the Transition Period
Number of patients reporting at least one treatment-emergent adverse event between weeks 52 and 78
Time frame: Week 52 through week 78
Incidence of Antidrug Antibodies (ADAs) in the Main Treatment Period
Number of patients with confirmed positive antidrug antibodies (ADAs) post-baseline through Week 52
Time frame: Anytime Post Baseline through Week 52
Incidence of Antidrug Antibodies (ADAs) in the Transition Period
Number of patients with confirmed positive antidrug antibodies (ADAs) at Week 65
Time frame: Anytime in Week 52 through Week 78
Percent Change From Baseline in Femoral Neck BMD at Week 52
Percent change from baseline in femoral neck bone mineral density (BMD) based on centrally assessed dual energy X ray absorptiometry (DXA)at week 52
Time frame: Baseline through Week 52
Percent Change From Baseline in Total Hip BMD at Week 52
Percent change from baseline in total hip bone mineral density (BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 52
Time frame: Baseline through Week 52
Number of TEAEs Leading to Patient Withdraw From the Study
Number of patients that withdraw or are removed from the study due to treatment emergent adverse events from both the main and transition treatment periods.
Time frame: Main Treatment Period = Baseline-Week 52; Transition period = Week 52-78
Local Tolerability at Injection Site
Number of patients who report Injection Site Reactions at Day 1, Week 26, or Week 52.
Time frame: Main Treatment Period = Day 1 & Week 26; Transition Treatment Period = Week 52
| Milestone | TVB-009 Main Treatment Period | PROLIA Main Treatment Period | TVB-009 Main / TVB-009 Transition Period | PROLIA Main / PROLIA Transition Period | PROLIA Main / TVB-009 Transition Period |
|---|---|---|---|---|---|
| Started | 166 | 166 | 0 | 0 | 0 |
| Completed | 148 | 143 | 0 | 0 | 0 |
| Not completed | 18 | 23 | 0 | 0 | 0 |
| Withdrew: Adverse event | 3 | 7 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 13 | 12 | 0 | 0 | 0 |
| Withdrew: Multiple other reasons | 2 | 4 | 0 | 0 | 0 |
| Milestone | TVB-009 Main Treatment Period | PROLIA Main Treatment Period | TVB-009 Main / TVB-009 Transition Period | PROLIA Main / PROLIA Transition Period | PROLIA Main / TVB-009 Transition Period |
|---|---|---|---|---|---|
| Started | 0 | 0 | 148 | 72 | 71 |
| Completed | 0 | 0 | 140 | 67 | 69 |
| Not completed | 0 | 0 | 8 | 5 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 7 | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Multiple other reasons | 0 | 0 | 1 | 2 | 1 |
Percent change from baseline in lumbar spine bone mineral density (LS BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 52
| percentage of change from baseline | TVB-009 Main Treatment Period | PROLIA Main Treatment Period |
|---|---|---|
| Percent Change From Baseline in LS-BMD at Week 52 | 4.76 (3.82 to 5.69) | 4.54 (3.62 to 5.47) |
Percent change from baseline in serum C-telopeptide cross-link of type 1 collagen at week 26
| percentage of change from baseline | TVB-009 Main Treatment Period | PROLIA Main Treatment Period |
|---|---|---|
| Percent Change From Baseline in sCTX-1 at Week 26 | -56.05 (-64.99 to -47.12) | -65.13 (-74.09 to -56.17) |
Percent change from baseline in lumbar spine bone mineral density (LS BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 26
| percentage of change from baseline | TVB-009 Main Treatment Period | PROLIA Main Treatment Period |
|---|---|---|
| Percent Change From Baseline in LS-BMD at Week 26 | 3.70 ± 4.294 | 3.62 ± 3.815 |
Percent change from baseline in femoral neck bone mineral density (BMD) based on centrally assessed dual energy X ray absorptiometry (DXA)at week 26
| percentage of change from baseline | TVB-009 Main Treatment Period | PROLIA Main Treatment Period |
|---|---|---|
| Percent Change From Baseline in Femoral Neck BMD at Week 26 | 1.87 ± 4.877 | 2.01 ± 3.611 |
Percent change from baseline in total hip bone mineral density (BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 26
| percentage of change from baseline | TVB-009 Main Treatment Period | PROLIA Main Treatment Period |
|---|---|---|
| Percent Change From Baseline in Total Hip BMD at Week 26 | 1.89 ± 3.488 | 2.02 ± 2.526 |
Percent change from baseline in serum C-telopeptide cross-link of type 1 collagen
| percentage of change from baseline | TVB-009 Main Treatment Period | PROLIA Main Treatment Period |
|---|---|---|
| Percent Change From Baseline in sCTX-1 | -57.91 ± 44.161 | -68.80 ± 35.846 |
Proportion of patients with suppression of serum C-telopeptide cross-link of type 1 collagen at week 4
| Percentage of participants | TVB-009 Main Treatment Period | PROLIA Main Treatment Period |
|---|---|---|
| Percentage of Participatns With sCTX-1 Suppression at Week 4 | 94.2 | 94.0 |
Percent change from baseline in procollagen type 1 N propeptide (P1NP) to Week 52
| percentage of change from baseline | TVB-009 Main Treatment Period | PROLIA Main Treatment Period |
|---|---|---|
| Percent Change From Baseline in P1NP | -56.43 ± 35.431 | -62.03 ± 33.712 |
Number of patients with who experienced any new fractures up to week 52.
| number participants with fractures | TVB-009 Main Treatment Period | PROLIA Main Treatment Period |
|---|---|---|
| Number of Fractures up to Week 52 | 3 | 5 |
Percent change from week 52 in lumbar spine bone mineral density (LS BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 78
| percentage of change from baseline | TVB-009 Main / TVB-009 Transition Period | PROLIA Main / PROLIA Transition Period | PROLIA Main / TVB-009 Transition Period |
|---|---|---|---|
| Percent Change From Week 52 in LS-BMD by DXA at Week 78 | 0.82 ± 3.120 | 1.15 ± 3.440 | 1.24 ± 3.069 |
Percent change from week 52 in femoral neck bone mineral density (LS BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 78
| Percent change from week 52 | TVB-009 Main / TVB-009 Transition Period | PROLIA Main / PROLIA Transition Period | PROLIA Main / TVB-009 Transition Period |
|---|---|---|---|
| Percent Change From Week 52 in Femoral Neck BMD by DXA at Week 78 | 0.38 ± 3.525 | 0.80 ± 3.560 | 0.94 ± 3.082 |
Percent change from week 52 in total hip bone mineral density (LS BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 78
| Percent change from week 52 | TVB-009 Main / TVB-009 Transition Period | PROLIA Main / PROLIA Transition Period | PROLIA Main / TVB-009 Transition Period |
|---|---|---|---|
| Percent Change From Week 52 in Total Hip BMD by DXA at Week 78 | 0.01 ± 2.089 | 0.66 ± 2.109 | 0.27 ± 2.264 |
Difference in the percent change from baseline in serum C-telopeptide cross-link of type 1 collagen from baseline to Week 78 as compared to baseline to Week 52
| Percent change from baseline | TVB-009 Main / TVB-009 Transition Period | PROLIA Main / PROLIA Transition Period | PROLIA Main / TVB-009 Transition Period |
|---|---|---|---|
| Difference Between Percent Change From Baseline in sCTX-1 Between Week 52 and Week 78 | 9.95 ± 41.612 | 13.17 ± 28.558 | 7.55 ± 36.509 |
The difference in the Percent change from baseline in procollagen type 1 N propeptide at Week 78 compared to Week 52.
| Percent change | TVB-009 Main / TVB-009 Transition Period | PROLIA Main / PROLIA Transition Period | PROLIA Main / TVB-009 Transition Period |
|---|---|---|---|
| Difference Between Percent Change From Baseline in P1NP Between Week 52 and Week 78 | 3.95 ± 23.376 | 4.83 ± 14.551 | 2.89 ± 39.804 |
Number of patients experiencing new fractures between week 52 and week 78
| Number participants with fractures | TVB-009 Main / TVB-009 Transition Period | PROLIA Main / PROLIA Transition Period | PROLIA Main / TVB-009 Transition Period |
|---|---|---|---|
| Number of Patients With Fractures Between Week 52 and Week 78 | 1 | 0 | 1 |
Number of patients reporting at least one treatment-emergent adverse event up to week 52
| Participants | TVB-009 Main Treatment Period | PROLIA Main Treatment Period |
|---|---|---|
| TEAE Related to Study Drug | 19 | 13 |
| TEAE Related to Medical Device | 0 | 0 |
| TEAE Not Related to Study Drug | 104 | 95 |
| No TEAEs Reported | 43 | 57 |
Number of patients reporting at least one treatment-emergent adverse event between weeks 52 and 78
| Participants | TVB-009 Main / TVB-009 Transition Period | PROLIA Main / PROLIA Transition Period | PROLIA Main / TVB-009 Transition Period |
|---|---|---|---|
| TEAE Related to Study Drug | 2 | 0 | 0 |
| TEAE Related to Medical Device | 0 | 0 | 0 |
| TEAE Not Related to Study Drug | 48 | 20 | 26 |
| No TEAE Reported | 98 | 52 | 45 |
Number of patients with confirmed positive antidrug antibodies (ADAs) post-baseline through Week 52
| Participants | TVB-009 Main Treatment Period | PROLIA Main Treatment Period |
|---|---|---|
| ADA Status — Positive | 11 | 25 |
| ADA Status — Positive, Not Treatment Related | 8 | 11 |
| ADA Status — Negative | 147 | 129 |
| Neutralizing ADA Status Among Positive — Positive | 1 | 2 |
| Neutralizing ADA Status Among Positive — Positive, Not Treatment Related | 0 | 0 |
| Neutralizing ADA Status Among Positive — Negative | 10 | 23 |
Number of patients with confirmed positive antidrug antibodies (ADAs) at Week 65
| Participants | TVB-009 Main / TVB-009 Transition Period | PROLIA Main / PROLIA Transition Period | PROLIA Main / TVB-009 Transition Period |
|---|---|---|---|
| ADA Status — Positive | 7 | 5 | 4 |
| ADA Status — Positive, Not Treatment Related | 7 | 4 | 1 |
| ADA Status — Negative | 133 | 61 | 65 |
| Neutralizing ADA Status Among Positive — Positive | 1 | 0 | 0 |
| Neutralizing ADA Status Among Positive — Positive, Not Treatment Related | 0 | 0 | 0 |
| Neutralizing ADA Status Among Positive — Negative | 6 | 5 | 4 |
Percent change from baseline in femoral neck bone mineral density (BMD) based on centrally assessed dual energy X ray absorptiometry (DXA)at week 52
| Percent change from baseline | TVB-009 Main Treatment Period | PROLIA Main Treatment Period |
|---|---|---|
| Percent Change From Baseline in Femoral Neck BMD at Week 52 | 2.39 ± 5.795 | 2.34 ± 3.780 |
Percent change from baseline in total hip bone mineral density (BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 52
| Percent change from baseline | TVB-009 Main Treatment Period | PROLIA Main Treatment Period |
|---|---|---|
| Percent Change From Baseline in Total Hip BMD at Week 52 | 2.67 ± 3.981 | 3.00 ± 2.768 |
Number of patients that withdraw or are removed from the study due to treatment emergent adverse events from both the main and transition treatment periods.
| Participants | TVB-009 Main Treatment Period | PROLIA Main Treatment Period | TVB-009 Main / TVB-009 Transition Period | PROLIA Main / PROLIA Transition Period | PROLIA Main / TVB-009 Transition Period |
|---|---|---|---|---|---|
| Number of TEAEs Leading to Patient Withdraw From the Study | 3 | 7 | 0 | 0 | 0 |
Number of patients who report Injection Site Reactions at Day 1, Week 26, or Week 52.
| Participants | TVB-009 Main Treatment Period | PROLIA Main Treatment Period | TVB-009 Main / TVB-009 Transition Period | PROLIA Main / PROLIA Transition Period | PROLIA Main / TVB-009 Transition Period |
|---|---|---|---|---|---|
| Day 1 — Erythema | 5 | 4 | — | — | — |
| Day 1 — Ecchymosis | 4 | 2 | — | — | — |
| Day 1 — Induration | 2 | 3 | — | — | — |
| Day 1 — Tenderness | 3 | 4 | — | — | — |
| Day 1 — Warmth | 0 | 1 | — | — | — |
| Day 1 — Swelling | 2 | 1 | — | — | — |
| Day 1 — Pain | 6 | 5 | — | — | — |
| Day 1 — No Reaction | 144 | 145 | — | — | — |
| Week 26 — Erythema | 2 | 4 | — | — | — |
| Week 26 — Ecchymosis | 3 | 0 | — | — | — |
| Week 26 — Induration | 2 | 0 | — | — | — |
| Week 26 — Tenderness | 1 | 1 | — | — | — |
| Week 26 — Warmth | 0 | 1 | — | — | — |
| Week 26 — Swelling | 1 | 1 | — | — | — |
| Week 26 — Pain | 7 | 4 | — | — | — |
| Week 26 — No Reaction | 142 | 142 | — | — | — |
| Week 52 — Erythema | — | — | 2 | 2 | 2 |
| Week 52 — Ecchymosis | — | — | 3 | 0 | 1 |
| Week 52 — Induration | — | — | 3 | 3 | 0 |
| Week 52 — Tenderness | — | — | 1 | 1 | 1 |
| Week 52 — Warmth | — | — | 0 | 2 | 0 |
| Week 52 — Swelling | — | — | 0 | 1 | 1 |
| Week 52 — Pain | — | — | 6 | 4 | 3 |
| Week 52 — No Reaction | — | — | 133 | 59 | 63 |
Collected over The Main Treatment Period collected adverse event data for a 52 week period (baseline to week 52). The transitional period collected adverse event data for a 26 week period (week 52 to week 78).. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TVB-009 Main Treatment Period | 0/166 (0%) | 8/166 (4.8%) | 123/166 (74.1%) |
| PROLIA Main Treatment Period | 0/165 (0%) | 6/165 (3.6%) | 108/165 (65.5%) |
| TVB-009 Main / TVB-009 Transition Period | 0/148 (0%) | 5/148 (3.4%) | 42/148 (28.4%) |
| PROLIA Main / PROLIA Transition Period | 0/72 (0%) | 0/72 (0%) | 20/72 (27.8%) |
| PROLIA Main / TVB-009 Transition Period | 0/71 (0%) | 1/71 (1.4%) | 11/71 (15.5%) |
| Event | TVB-009 Main Treatment Period | PROLIA Main Treatment Period | TVB-009 Main / TVB-009 Transition Period | PROLIA Main / PROLIA Transition Period | PROLIA Main / TVB-009 Transition Period |
|---|---|---|---|---|---|
| CholelithiasisHepatobiliary disorders | 1/166 | 0/165 | 0/148 | 0/72 | 1/71 |
| COVID-19 pneumoniaInfections and infestations | 0/166 | 1/165 | 1/148 | 0/72 | 0/71 |
| MalaiseGeneral disorders | 0/166 | 0/165 | 1/148 | 0/72 | 0/71 |
| Helicobacter infectionInfections and infestations | 0/166 | 0/165 | 1/148 | 0/72 | 0/71 |
| Bone cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/166 | 0/165 | 1/148 | 0/72 | 0/71 |
| Urinary incontinenceRenal and urinary disorders | 0/166 | 0/165 | 1/148 | 0/72 | 0/71 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/166 | 0/165 | 1/148 | 0/72 | 0/71 |
| Atrial flutterCardiac disorders | 0/166 | 1/165 | 0/148 | 0/72 | 0/71 |
| Myocardial ischaemiaCardiac disorders | 0/166 | 1/165 | 0/148 | 0/72 | 0/71 |
| Cholecystitis acuteHepatobiliary disorders | 0/166 | 1/165 | 0/148 | 0/72 | 0/71 |
| Event | TVB-009 Main Treatment Period | PROLIA Main Treatment Period | TVB-009 Main / TVB-009 Transition Period | PROLIA Main / PROLIA Transition Period | PROLIA Main / TVB-009 Transition Period |
|---|---|---|---|---|---|
| Vitamin D deficiencyMetabolism and nutrition disorders | 34/166 | 21/165 | 2/148 | 0/72 | 0/71 |
| COVID-19Infections and infestations | 17/166 | 22/165 | 3/148 | 0/72 | 1/71 |
| HypercalcaemiaMetabolism and nutrition disorders | 14/166 | 19/165 | 4/148 | 2/72 | 2/71 |
| HeadacheNervous system disorders | 16/166 | 15/165 | 4/148 | 1/72 | 3/71 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 14/166 | 13/165 | 4/148 | 4/72 | 0/71 |
| NasopharyngitisInfections and infestations | 7/166 | 9/165 | 4/148 | 5/72 | 0/71 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 6/166 | 10/165 | 3/148 | 3/72 | 0/71 |
| Vitamin D decreasedInvestigations | 10/166 | 5/165 | 0/148 | 0/72 | 1/71 |
| Back painMusculoskeletal and connective tissue disorders | 9/166 | 6/165 | 8/148 | 2/72 | 0/71 |
| HypertensionVascular disorders | 8/166 | 8/165 | 1/148 | 0/72 | 0/71 |
The baseline characteristics are only presented for the Treatment Period Arms as the same subject were employed in the Transition Period.
| Age, Continuous(years) | TVB-009 Main Treatment Period | PROLIA Main Treatment Period | Total |
|---|---|---|---|
| Mean | 68.5 ± 5.69 | 67.7 ± 5.56 | 68.1 ± 5.63 |
| Sex: Female, Male(Participants) | TVB-009 Main Treatment Period | PROLIA Main Treatment Period | Total |
|---|---|---|---|
| Female | 166 | 166 | 332 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | TVB-009 Main Treatment Period | PROLIA Main Treatment Period | Total |
|---|---|---|---|
| Hispanic or Latino | 23 | 18 | 41 |
| Not Hispanic or Latino | 143 | 148 | 291 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | TVB-009 Main Treatment Period | PROLIA Main Treatment Period | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 |
| White | 165 | 164 | 329 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(participants) | TVB-009 Main Treatment Period | PROLIA Main Treatment Period | Total |
|---|---|---|---|
| Hungary | 11 | 6 | 17 |
| United States | 34 | 35 | 69 |
| Czechia | 21 | 19 | 40 |
| Ukraine | 13 | 12 | 25 |
| Poland | 30 | 37 | 67 |
| Georgia | 17 | 9 | 26 |
| Slovakia | 6 | 13 | 19 |
| Bulgaria | 22 | 20 | 42 |
| Germany | 1 | 1 | 2 |
| Russia | 11 | 14 | 25 |
| Previous Use of Biophosphonates(Participants) | TVB-009 Main Treatment Period | PROLIA Main Treatment Period | Total |
|---|---|---|---|
| Yes | 21 | 21 | 42 |
| No | 145 | 145 | 290 |
| Prior Fractures(Participants) | TVB-009 Main Treatment Period | PROLIA Main Treatment Period | Total |
|---|---|---|---|
| Yes | 37 | 38 | 75 |
| No | 129 | 128 | 257 |
| Taking Calcium & Vitamin D Supplements(Participants) | TVB-009 Main Treatment Period | PROLIA Main Treatment Period | Total |
|---|---|---|---|
| Yes | 28 | 28 | 56 |
| No | 9 | 10 | 19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2021 to primary completion in Dec 2022, 21 months.
Results were first posted in Apr 2024, 1 year 3 months after primary completion.
Of 29 industry-sponsored phase 3 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's 21 months is below that.
Counting every sponsor, half of 30 studies reached it within 24 months; a quarter within 20 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab
Osteoporosis, Postmenopausal →